SGLT inhibitors will trigger growth in heart failure market
The market for heart failure (HF) therapies is expected to grow from $3.7 billion in 2018 to $22.1 billion in 2028 across the eight major markets (8MM: USA, France, Germany, Italy, Spain, the UK, Japan and China.
This is an impressive compound annual growth rate (CAGR) of 19.5%, according to analytics company GlobalData.
The company’s latest report, ‘ Heart Failure: Global Drug Forecast and Market Analysis to 2028’, states that the generic-saturated market will experience major growth over the next 10 years, which can be attributed to the much anticipated label expansion of well-known anti-diabetic sodium-glucose co-transporter (SGLT) inhibitors and other novel pipeline agents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze